{"id":10150,"date":"2026-05-11T06:41:59","date_gmt":"2026-05-11T11:41:59","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10150"},"modified":"2026-05-11T06:48:35","modified_gmt":"2026-05-11T11:48:35","slug":"nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/","title":{"rendered":"Nanoscope Therapeutics presentar\u00e1 resultados cl\u00ednicos y de fabricaci\u00f3n avanzados en la reuni\u00f3n anual de la ASGCT de 2026."},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10150\" class=\"elementor elementor-10150\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3 style=\"text-align: center;\"><i>Las presentaciones destacar\u00e1n la investigaci\u00f3n en curso sobre los posibles beneficios de la visi\u00f3n bilateral y del color.<\/i>\u00a0<i>Nanoscope&#8217;s optogenetic therapy platform<\/i><\/h3><p><strong><span class=\"legendSpanClass\">DALLAS<\/span>,\u00a0<span class=\"legendSpanClass\">11 de mayo de 2026<\/span> <\/strong>\u2014\u00a0<a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda comprometida con la restauraci\u00f3n de la visi\u00f3n en pacientes ciegos en entornos del mundo real mediante el desarrollo y la comercializaci\u00f3n de nuevas terapias gen\u00e9ticas para enfermedades degenerativas de la retina, anunci\u00f3 hoy m\u00faltiples presentaciones en el 29<sup>th<\/sup>\u00a0reuni\u00f3n anual de la Sociedad Americana de Terapia G\u00e9nica y Celular (<a href=\"https:\/\/annualmeeting.asgct.org\/?_gl=1*kcvf3w*_ga*MjY4NDA4NzQ0LjE3NzgwNzg5MTQ.*_ga_Q37QKR6TCJ*czE3NzgwNzg5MTQkbzEkZzEkdDE3NzgwNzg5MzgkajM2JGwwJGgw*_gcl_au*NTY1NzU0NzY1LjE3NzgwNzg5MTI.\" target=\"_blank\" rel=\"nofollow noopener\">ASGCT 2026<\/a>), que se celebrar\u00e1 en Boston del 11 al 15 de mayo.<sup>th<\/sup>, 2026. Nanoscope&#8217;s presentations will be centered around the company&#8217;s\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/how-it-works\/\" target=\"_blank\" rel=\"nofollow noopener\">Terapia optogen\u00e9tica MCO-010<\/a>\u00a0para enfermedades degenerativas de la retina. MCO-010 es el programa m\u00e1s avanzado en la plataforma MCO (opsina multicaracter\u00edstica) y la primera y \u00fanica terapia independiente de mutaciones.\u00a0<a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(25)00205-9\" target=\"_blank\" rel=\"nofollow noopener\">Se ha demostrado que restaura la visi\u00f3n en pacientes con retinosis pigmentaria (RP) avanzada.<\/a>\u00a0mediante una inyecci\u00f3n intrav\u00edtrea est\u00e1ndar de una sola vez.<\/p><p>&#8220;We are excited to present expanded clinical observations highlighting the potential patient benefit of MCO-treatment, along with key learnings from our AAV manufacturing efforts,&#8221; said Dr. Samarendra Mohanty, co-founder and President of Nanoscope. &#8220;We look forward to sharing the important updates, including the positive therapeutic effects observed in RP and Stargardt disease patients, adding to our enthusiasm at Nanoscope as we near completion of the US BLA submission for MCO-010.&#8221;<\/p><p>A continuaci\u00f3n se detallan las presentaciones de la reuni\u00f3n:<\/p><p><a href=\"https:\/\/annualmeeting.asgct.org\/program-workshops\" target=\"_blank\" rel=\"nofollow noopener\">Programa completo<\/a><br class=\"dnr\" \/>Presentaciones en el podio:<\/p><ul type=\"disc\"><li><b>Mejora funcional bilateral en pacientes tras la administraci\u00f3n unilateral de una prote\u00edna sint\u00e9tica bioingenierizada con sensibilidad a la luz de amplio espectro mediante c\u00e9lulas retinianas basadas en AAV.<\/b>\u00a0<b>Tuesday, May 12, 04:00 PM &#8211; 04:15 PM ET; MCEC Room 258ABC (Level 2)\u00a0<\/b>\u2013 El Dr. Vinit Mahajan presentar\u00e1 observaciones bilaterales tras la administraci\u00f3n de MCO-010 en modelos no cl\u00ednicos y en ensayos cl\u00ednicos de pacientes con retinosis pigmentaria y enfermedad de Stargardt.<\/li><\/ul><ul type=\"disc\"><li><b>Mechanism and clinical evidence of MCO-010 optogenetic therapy improving color discrimination in patients with outer retinal degeneration, Friday, May 15, 04:15 PM &#8211; 04:30 PM ET MCEC Room 210ABC (Level 2)\u00a0<\/b>\u2013 El Dr. Samarendra Mohanty presentar\u00e1 informaci\u00f3n sobre la respuesta de la visi\u00f3n del color en pacientes con retinosis pigmentaria y enfermedad de Stargardt tratados con MCO-010, y el mecanismo que subyace a la sensibilidad al color.<\/li><\/ul><p>Presentaciones en formato p\u00f3ster:<\/p><ul type=\"disc\"><li><b>Orthogonal Quantitation of Replication-Competent AAV in AAV Manufacturing, Wednesday, May 13, 05:00 PM &#8211; 06:30 PM ET;\u00a0<\/b><b>P\u00f3ster #2207 (Pabell\u00f3n B2-C del MCEC, Nivel de Exposiciones)\u00a0<\/b>\u2013 Presentando el Dr. Amir Singh<\/li><\/ul><ul type=\"disc\"><li><b>Chemistry, Manufacturing, and Controls (CMC) Challenges in Gene Therapy Regulatory Approvals: Insights from Approved Products and FDA Complete Response Letters, Wednesday, May 13, 05:00 PM &#8211; 06:30 PM ET;\u00a0<\/b><b>P\u00f3ster #2235 (Pabell\u00f3n B2-C del MCEC, Nivel de Exposiciones)\u00a0<\/b>\u2013 Presentaci\u00f3n del Dr. Ananta Ayyagari<\/li><\/ul><p>Los miembros del equipo de Nanoscope tambi\u00e9n estar\u00e1n disponibles para reuniones durante la conferencia ASGCT.<\/p><p><b>Acerca de la plataforma MCO<br class=\"dnr\" \/><\/b>MCO es una plataforma terap\u00e9utica intrav\u00edtrea de una sola aplicaci\u00f3n, ambulatoria y aplicable a cualquier enfermedad, dise\u00f1ada para restaurar la visi\u00f3n en pacientes con degeneraci\u00f3n de fotorreceptores, incluyendo retinosis pigmentaria (RP), enfermedad de Stargardt (ES) y atrofia geogr\u00e1fica (AG). Al activar las c\u00e9lulas bipolares de la retina, altamente densas, para que sean sensibles a la luz, MCO aprovecha el circuito visual restante tras la muerte de los fotorreceptores. El tratamiento con MCO no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, lo que permite una amplia aplicabilidad en pacientes dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><b>Acerca de Nanoscope Therapeutics<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (RP) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), se ha iniciado una presentaci\u00f3n continua de BLA a la FDA. Si se aprueba, MCO-010 tiene el potencial de ser el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar una\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">Ensayo de registro de fase 3<\/a>\u00a0En 2026, MCO-010 recibi\u00f3 las designaciones de v\u00eda r\u00e1pida y medicamento hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, as\u00ed como las designaciones Sakigake y hu\u00e9rfana de la PMDA para distrofias retinianas hereditarias (IRD) y las designaciones hu\u00e9rfana de la EMA y la SFDA para IRD. Se espera que un programa de fase 2 para MCO en atrofia geogr\u00e1fica (GA) comience en 2026. Otros programas listos para IND incluyen la amaurosis cong\u00e9nita de Leber (LCA).<\/p><p><b>Contacto:<\/b><br class=\"dnr\" \/>Nanoscope Therapeutics, Inc.<br class=\"dnr\" \/>+1 (817) 857-1186<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Presentations will highlight the ongoing research behind potential bilateral and color vision benefits of\u00a0Nanoscope&#8217;s optogenetic therapy platform DALLAS,\u00a0May 11, 2026 &#8212;\u00a0Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced multiple presentations at the 29th\u00a0annual meeting [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10151,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10150","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-11T11:41:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-11T11:48:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting\",\"datePublished\":\"2026-05-11T11:41:59+00:00\",\"dateModified\":\"2026-05-11T11:48:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/\"},\"wordCount\":659,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASGCT26.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASGCT26.jpg\",\"datePublished\":\"2026-05-11T11:41:59+00:00\",\"dateModified\":\"2026-05-11T11:48:35+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASGCT26.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_ASGCT26.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/05\\\/11\\\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 resultados cl\u00ednicos y de fabricaci\u00f3n avanzados en la reuni\u00f3n anual de la ASGCT 2026 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-05-11T11:41:59+00:00","article_modified_time":"2026-05-11T11:48:35+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting","datePublished":"2026-05-11T11:41:59+00:00","dateModified":"2026-05-11T11:48:35+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/"},"wordCount":659,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASGCT26.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/","url":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/","name":"Nanoscope Therapeutics presentar\u00e1 resultados cl\u00ednicos y de fabricaci\u00f3n avanzados en la reuni\u00f3n anual de la ASGCT 2026 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASGCT26.jpg","datePublished":"2026-05-11T11:41:59+00:00","dateModified":"2026-05-11T11:48:35+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASGCT26.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_ASGCT26.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/05\/11\/nanoscope-therapeutics-to-present-advanced-clinical-and-manufacturing-findings-at-asgct-2026-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10150","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10150"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10150\/revisions"}],"predecessor-version":[{"id":10155,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10150\/revisions\/10155"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10151"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10150"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10150"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10150"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}